Home Prostate / Prostate Cancer Telix Enters Collaboration With DKFZ for Image-Guided Surgery for PC

Telix Enters Collaboration With DKFZ for Image-Guided Surgery for PC


Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery

Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men with prostate cancer.

Investigators from the DKFZ and Heidelberg University Clinic have been working on the development of a next-generation radiotracer — a radioactive compound that may be administered to patients to “light up” tumors in positron emission tomography (PET) scans. It is based on Telix’s TLX591-CDx (68Ga-PSMA-11), marketed in the U.S. under the brand name Illumet.

Besides emitting radiation required for PET, the new compound also contains a fluorescing agent (fluorophore) that is visible through optical imaging. For this reason, the compound may be simultaneously used as a standard radiotracer agent to image prostate cancer through PET, and as a fluorescent agent to guide surgeons during prostate surgery.

Image-guided fluorescence imaging is a standard feature of many modern systems. It is based on the use of automated surgical robots that are widely used across the globe during urologic surgeries. One example is the 


This site uses Akismet to reduce spam. Learn how your comment data is processed.